Nab-paclitaxel for the treatment of aggressive metastatic breast cancer

Stefan Glück

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.

Original languageEnglish
Pages (from-to)221-227
Number of pages7
JournalClinical Breast Cancer
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
Therapeutics
Triple Negative Breast Neoplasms
Taxoids
130-nm albumin-bound paclitaxel
Progesterone Receptors
Estrogen Receptors
Early Diagnosis
Survival Rate
Clinical Trials
Hormones
Neoplasm Metastasis
human ERBB2 protein
Neoplasms

Keywords

  • Aggressive
  • Metastatic breast cancer
  • nab-Paclitaxel
  • Poor prognosis
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nab-paclitaxel for the treatment of aggressive metastatic breast cancer. / Glück, Stefan.

In: Clinical Breast Cancer, Vol. 14, No. 4, 01.01.2014, p. 221-227.

Research output: Contribution to journalArticle

@article{49350b2cf2094d68a67130ea03d9bfe6,
title = "Nab-paclitaxel for the treatment of aggressive metastatic breast cancer",
abstract = "Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24{\%}. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.",
keywords = "Aggressive, Metastatic breast cancer, nab-Paclitaxel, Poor prognosis, Triple-negative breast cancer",
author = "Stefan Gl{\"u}ck",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2014.02.001",
language = "English",
volume = "14",
pages = "221--227",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Nab-paclitaxel for the treatment of aggressive metastatic breast cancer

AU - Glück, Stefan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.

AB - Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.

KW - Aggressive

KW - Metastatic breast cancer

KW - nab-Paclitaxel

KW - Poor prognosis

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84904653755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904653755&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2014.02.001

DO - 10.1016/j.clbc.2014.02.001

M3 - Article

C2 - 24806278

AN - SCOPUS:84904653755

VL - 14

SP - 221

EP - 227

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -